Core Viewpoint - Zhengye Biological (ZYBT) experienced a stock price increase of 3.92% on August 11, reaching $5.414 per share, with a total market capitalization of $257 million [1]. Financial Performance - As of December 31, 2024, Zhengye Biological reported total revenue of 186 million RMB, representing a year-on-year decrease of 11.95% [1]. - The net profit attributable to the parent company was 11.311 million RMB, reflecting a significant year-on-year decline of 64.04% [1]. Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1]. - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1].
正业生物上涨3.92%，报5.414美元/股，总市值2.57亿美元